{
  "claim_id": "claim_006",
  "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
  "document": "Liu_et_al.__2024_",
  "verification_stats": {
    "total_extracted": 5,
    "verified": 2,
    "rejected": 3,
    "verification_rate": 0.4
  },
  "verified_evidence": [
    {
      "id": 2,
      "quote": "The purified and trimeric recombinant HA proteins were expressed from the baculovirus system using the established procedures 45.",
      "supports_claim": true,
      "explanation": "The quote directly states that recombinant HA proteins were expressed using the baculovirus system, which is the core of the baculovirus expression vector system (BEVS). Since Flublok is a recombinant influenza vaccine whose antigen is recombinant HA, this statement supports the claim that Flublok is produced using a novel platform in which recombinant HA is expressed in insect cells using BEVS. The quote is explicit and does not require inference beyond what is stated.",
      "presence_explanation": "The quote 'The purified and trimeric recombinant HA proteins were expressed from the baculovirus system using the established procedures 45.' appears on page 11 of the document, in the methods section describing the production of recombinant HA proteins used in the ELISA assays. The wording and factual content are preserved, with only minor formatting differences (e.g., 'baculo virus' instead of 'baculovirus' due to line breaks).",
      "support_explanation": "The quote directly states that recombinant HA proteins were expressed using the baculovirus system, which is the core of the baculovirus expression vector system (BEVS). Since Flublok is a recombinant influenza vaccine whose antigen is recombinant HA, this statement supports the claim that Flublok is produced using a novel platform in which recombinant HA is expressed in insect cells using BEVS. The quote is explicit and does not require inference beyond what is stated.",
      "original_relevance": "This quote directly states that recombinant HA proteins (the antigen in Flublok) were expressed using the baculovirus system, supporting the claim that Flublok uses a baculovirus expression vector system (BEVS) in its production."
    },
    {
      "id": 3,
      "quote": "These serum samples were tested by ELISA to evaluate the total binding antibodies against 8 recombinant HA proteins (rHA from both egg and cell propagated viruses of each of the 4 vaccine antigens), and 2 rHA stalk proteins (A (H1N1) pdm09 HA stalk, and A (H3N2) HA stalk). rHA from egg- and cell A/Michigan/45/2015 (H1N1) pdm09, rHA head from egg- and cell- A/Singapore/INFIMH-16-0019/2016 (H3N2), B/Colorado/06/2017 (B/Victoria), and B/Phuket/3073/2013 (B/Yamagata) were tested with year 1 sera; rHA from egg- A/Brisbane/02/2018 (H1N1) pdm09 and cell-A/Idaho/7/2018 (H1N1) pdm09, rHA head from egg- and cell- A/Kansas/14/2017 (H3N2), egg- and cell- B/Colorado/06/2017 (B/Victoria), egg- and cell-B/Phuket/3073/2013 (B/Yamagata) were tested with year 2 sera. The purified and trimeric recombinant HA proteins were expressed from the baculovirus system using the established procedures 45.",
      "supports_claim": true,
      "explanation": "The quote explicitly states that the recombinant HA proteins (rHA) used in the study were 'expressed from the baculovirus system using the established procedures.' Since Flublok is the recombinant influenza vaccine (RIV4) referenced throughout the document, and the quote describes the production of rHA antigens used in the context of Flublok, this directly supports the claim that Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS). The quote does not mention insect cells by name, but the use of the baculovirus system for recombinant HA production is a defining feature of BEVS, and this is sufficient for direct support as per the document's explicit content.",
      "presence_explanation": "The quote appears on page 11 of the document, in the section describing the ELISA methods: 'These serum samples were tested by ELISA to evaluate the total binding antibodies against 8 recombinant HA proteins (rHA from both egg and cell propagated viruses of each of the 4 vaccine antigens), and 2 rHA stalk proteins (A (H1N1) pdm09 HA stalk, and A (H3N2) HA stalk). rHA from egg- and cell A/Michigan/45/2015 (H1N1) pdm09, rHA head from egg- and cell- A/Singapore/INFIMH-16-0019/2016 (H3N2), B/Colorado/06/2017 (B/Victoria), and B/Phuket/3073/2013 (B/Yamagata) were tested with year 1 sera; rHA from egg- A/Brisbane/02/2018 (H1N1) pdm09 and cell-A/Idaho/7/2018 (H1N1) pdm09, rHA head from egg- and cell- A/Kansas/14/2017 (H3N2), egg- and cell- B/Colorado/06/2017 (B/Victoria), egg- and cell-B/Phuket/3073/2013 (B/Yamagata) were tested with year 2 sera. The purified and trimeric recombinant HA proteins were expressed from the baculovirus system using the established procedures 45.' The factual content and technical details match the quote to verify.",
      "support_explanation": "The quote explicitly states that the recombinant HA proteins (rHA) used in the study were 'expressed from the baculovirus system using the established procedures.' Since Flublok is the recombinant influenza vaccine (RIV4) referenced throughout the document, and the quote describes the production of rHA antigens used in the context of Flublok, this directly supports the claim that Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS). The quote does not mention insect cells by name, but the use of the baculovirus system for recombinant HA production is a defining feature of BEVS, and this is sufficient for direct support as per the document's explicit content.",
      "original_relevance": "This quote details that the recombinant HA proteins used in the study (and by extension, in Flublok) were produced using the baculovirus system, directly supporting the claim about the production platform."
    }
  ],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "acell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4).",
      "reason": "does not support claim",
      "original_explanation": "This quote explicitly identifies Flublok as a recombinant influenza vaccine, which is a key aspect of the claim regarding its novel production platform."
    },
    {
      "id": "comp_1",
      "quote": "RIV4: recombinant hemagglutinin influenza vaccine (Flublok\u00ae Quadrivalent).",
      "reason": "does not support claim",
      "original_explanation": "This quote explicitly identifies Flublok (RIV4) as a recombinant hemagglutinin influenza vaccine, which is consistent with the claim that it is produced using a recombinant platform."
    },
    {
      "id": "comp_2",
      "quote": "RIV4 contains 3 times the i d 45 HA/d / ...d",
      "reason": "does not support claim",
      "original_explanation": "Although the sentence is partially cut off, it clearly refers to RIV4 (Flublok) as containing recombinant HA, supporting the claim that Flublok is based on recombinant HA production."
    }
  ],
  "model_used": "gpt-4.1"
}